July 19, 2018 / 12:14 PM / a year ago

Mersana Therapeutics cancer drug trial on partial hold by FDA

July 19 (Reuters) - Mersana Therapeutics said on Thursday its early-stage trial for its cancer drug has been put on partial hold by the U.S. health regulator after a patient's death was possibly related to the treatment.

No new patients will be enrolled in the study, but the current participants will continue to receive the drug, Mersana said in a statement.

Shares of the company were halted in premarket trade. (Reporting by Tamara Mathias in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below